ADVENT On Air https://www.ADVENTprogram.com en The latest updates in type 2 inflammatory science, brought to you by leading experts in the field. The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area. Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com. This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals. ©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302644 v2.0 07/2023 MAT-US-2304947 v1.0-P Exp. Date 07/07/2025 https://megaphone.imgix.net/podcasts/05a1629c-1073-11ee-9578-53af33debffe/image/Advent_OnAir_Logo_202401.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress ADVENT On Air https://www.ADVENTprogram.com no episodic ADVENT Program The latest updates in type 2 inflammatory science, brought to you by leading experts in the field. The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area. Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com. This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals. ©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302644 v2.0 07/2023 MAT-US-2304947 v1.0-P Exp. Date 07/07/2025 The latest updates in type 2 inflammatory science, brought to you by leading experts in the field.

The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area.

Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com.

This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals.


©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2302644 v2.0 07/2023

MAT-US-2304947 v1.0-P Exp. Date 07/07/2025

]]> ADVENT Program adventprogram.sanofi@gmail.com Breaking the Cycle: The OCS Burden in CRSwNP Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Luong: Served on advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron; Consultant to Maxwell Biosciences, Medtronic and Stryker; Grant funding from Eli Lily and Sanofi. Cornet: Marjolein Cornet has received speaker fees and participated in advisory board meetings for Regeneron Pharmaceuticals Inc., Sanofi Genzyme, GSK, ALK, Mylan, Stallergenes Greer and Medtronic. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2601160- 1.0 - 04/2026 Thu, 16 Apr 2026 16:17:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Luong: Served on advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron; Consultant to Maxwell Biosciences, Medtronic and Stryker; Grant funding from Eli Lily and Sanofi. Cornet: Marjolein Cornet has received speaker fees and participated in advisory board meetings for Regeneron Pharmaceuticals Inc., Sanofi Genzyme, GSK, ALK, Mylan, Stallergenes Greer and Medtronic. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2601160- 1.0 - 04/2026 Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts

highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care.


ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. 


This podcast is intended for healthcare professionals only.


Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

Speaker disclosures:

  • Luong: Served on advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron; Consultant to Maxwell Biosciences, Medtronic and Stryker; Grant funding from Eli Lily and Sanofi.
  • Cornet: Marjolein Cornet has received speaker fees and participated in advisory board meetings for Regeneron Pharmaceuticals Inc., Sanofi Genzyme, GSK, ALK, Mylan, Stallergenes Greer and Medtronic.


© 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2601160- 1.0 - 04/2026


]]> 862 Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors? Dr. Ikuo Hirano and Dr. Margaret (Peggy) Marcon highlight why dysphagia may be overlooked and share insights from their own clinical practice on how to unmask EoE behind patients' adaptive behaviors. Please note that this podcast was recorded prior to the passing of Dr. Hirano. His expertise and contributions to the field are honored and remembered with deep respect. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only.   Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Ikuo Hirano, MD has received consultation fees from Adare/Ellodi, Allakos, Pfizer/Arena, AstraZeneca, Celgene/Receptos, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calypso, Regeneron, Sanofi, Shire/Takeda, Phathom, Nexstone. He has participated in clinical trials for AstraZeneca, Celgene/BMS, Regeneron, Shire/Takeda, Ellodi/Adare, Allakos and been a member of Speaker Bureaus for Sanofi and Regeneron. Dr. Peggy Marcon has received fees from Nutricia, Sanofi for education. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304790 - 2.0 - 03/2026 MAT-US-2402674 v3.0 - P Expiration Date: 03/09/2028 Wed, 25 Mar 2026 17:04:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors? full ADVENT Program Dr. Ikuo Hirano and Dr. Margaret (Peggy) Marcon highlight why dysphagia may be overlooked and share insights from their own clinical practice on how to unmask EoE behind patients' adaptive behaviors. Please note that this podcast was recorded prior to the passing of Dr. Hirano. His expertise and contributions to the field are honored and remembered with deep respect. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only.   Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Ikuo Hirano, MD has received consultation fees from Adare/Ellodi, Allakos, Pfizer/Arena, AstraZeneca, Celgene/Receptos, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calypso, Regeneron, Sanofi, Shire/Takeda, Phathom, Nexstone. He has participated in clinical trials for AstraZeneca, Celgene/BMS, Regeneron, Shire/Takeda, Ellodi/Adare, Allakos and been a member of Speaker Bureaus for Sanofi and Regeneron. Dr. Peggy Marcon has received fees from Nutricia, Sanofi for education. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304790 - 2.0 - 03/2026 MAT-US-2402674 v3.0 - P Expiration Date: 03/09/2028 Dr. Ikuo Hirano and Dr. Margaret (Peggy) Marcon highlight why dysphagia may be overlooked and share insights from their own clinical practice on how to unmask EoE behind patients' adaptive behaviors.


Please note that this podcast was recorded prior to the passing of Dr. Hirano. His expertise and contributions to the field are honored and remembered with deep respect.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.

 

Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Dr. Ikuo Hirano, MD has received consultation fees from Adare/Ellodi, Allakos, Pfizer/Arena, AstraZeneca, Celgene/Receptos, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calypso, Regeneron, Sanofi, Shire/Takeda, Phathom, Nexstone. He has participated in clinical trials for AstraZeneca, Celgene/BMS, Regeneron, Shire/Takeda, Ellodi/Adare, Allakos and been a member of Speaker Bureaus for Sanofi and Regeneron.
  • Dr. Peggy Marcon has received fees from Nutricia, Sanofi for education.


© 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2304790 - 2.0 - 03/2026

MAT-US-2402674 v3.0 - P Expiration Date: 03/09/2028

]]> 1017 Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Simon Couillard: he has received non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Association Pulmonaire du Québec, the Academy of Medical Sciences, AstraZeneca, bioMérieux, Circassia Niox Group, and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Québec’s Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Circassia Niox Group and Valeo Pharma; he received consultancy fees for FirstThought, Apogee Therapeutics, Upstream Bio, AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Access Biotechnology and Access Industries; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and detains stock options for Biometry Inc – a company which is developing a FeNO device (myBiometry); he is co-inventor for the patent filed as ‘Method for alleviating dyspnea with neuromodulation’. He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners as well as therapeutic indications for Enerzair, and is a member of the asthma steering committee of the Canadian Thoracic Society, 2025-05-26 Dr. Sharon Dell: Grants and Research Support: Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, VertexPharmaceuticals; Honoraria or Consultation Fees: AstraZeneca, Novartis, Regeneron Pharmaceuticals Inc., Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2506512 - 1.0 - 01/2026 MAT-US-2600428 v1.0 - P Expiration Date: 01/16/2028 Fri, 30 Jan 2026 08:25:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Simon Couillard: he has received non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Association Pulmonaire du Québec, the Academy of Medical Sciences, AstraZeneca, bioMérieux, Circassia Niox Group, and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Québec’s Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Circassia Niox Group and Valeo Pharma; he received consultancy fees for FirstThought, Apogee Therapeutics, Upstream Bio, AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Access Biotechnology and Access Industries; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and detains stock options for Biometry Inc – a company which is developing a FeNO device (myBiometry); he is co-inventor for the patent filed as ‘Method for alleviating dyspnea with neuromodulation’. He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners as well as therapeutic indications for Enerzair, and is a member of the asthma steering committee of the Canadian Thoracic Society, 2025-05-26 Dr. Sharon Dell: Grants and Research Support: Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, VertexPharmaceuticals; Honoraria or Consultation Fees: AstraZeneca, Novartis, Regeneron Pharmaceuticals Inc., Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2506512 - 1.0 - 01/2026 MAT-US-2600428 v1.0 - P Expiration Date: 01/16/2028 Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.


ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  


This podcast is intended for healthcare professionals only.


Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:  

Dr. Simon Couillard: he has received non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Association Pulmonaire du Québec, the Academy of Medical Sciences, AstraZeneca, bioMérieux, Circassia Niox Group, and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Québec’s Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Circassia Niox Group and Valeo Pharma; he received consultancy fees for FirstThought, Apogee Therapeutics, Upstream Bio, AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Access Biotechnology and Access Industries; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and detains stock options for Biometry Inc – a company which is developing a FeNO device (myBiometry); he is co-inventor for the patent filed as ‘Method for alleviating dyspnea with neuromodulation’. He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners as well as therapeutic indications for Enerzair, and is a member of the asthma steering committee of the Canadian Thoracic Society, 2025-05-26

Dr. Sharon Dell: Grants and Research Support: Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, VertexPharmaceuticals; Honoraria or Consultation Fees: AstraZeneca, Novartis, Regeneron Pharmaceuticals Inc., Sanofi

 

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2506512 - 1.0 - 01/2026

MAT-US-2600428 v1.0 - P Expiration Date: 01/16/2028

]]> 1879 Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact Join Profs. Brusselle and Backer as they discuss the concept of disease modification in asthma. Join them as they highlight  the concept of disease modification in severe asthma, how it can be defined and objectively assessed, and the benefits for the patient when disease modification is a treatment target.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Vibeke Backer: has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. Dr. Guy Bruselle:  has received grants from Merck Sharp & Dohme and has recevied lecturer/consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503097 - 1.0 - 01/2026 MAT-US-2600873 v1.0 - P Expiration Date: 01/28/2028 Fri, 30 Jan 2026 08:15:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Join Profs. Brusselle and Backer as they discuss the concept of disease modification in asthma. Join them as they highlight  the concept of disease modification in severe asthma, how it can be defined and objectively assessed, and the benefits for the patient when disease modification is a treatment target.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Vibeke Backer: has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. Dr. Guy Bruselle:  has received grants from Merck Sharp & Dohme and has recevied lecturer/consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503097 - 1.0 - 01/2026 MAT-US-2600873 v1.0 - P Expiration Date: 01/28/2028 Join Profs. Brusselle and Backer as they discuss the concept of disease modification in asthma. Join them as they highlight  the concept of disease modification in severe asthma, how it can be defined and objectively assessed, and the benefits for the patient when disease modification is a treatment target.

 

ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  


This podcast is intended for healthcare professionals only.


Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

Speaker disclosures:  

  • Dr. Vibeke Backer: has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC.
  • Dr. Guy Bruselle:  has received grants from Merck Sharp & Dohme and has recevied lecturer/consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi

 

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2503097 - 1.0 - 01/2026

MAT-US-2600873 v1.0 - P Expiration Date: 01/28/2028

]]> 1233 Be on the Lookout for EoE: The Importance of Early Diagnosis Hear Dr. Seema Aceves and Ms. Hilary Ugras discuss the importance of early diagnosis and intervention for patients with EoE, opportunities for early diagnosis, and unmasking the adaptive behaviors of patients with EoE.  ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  Learn more at ADVENTprogram.com.  This podcast is intended for healthcare professionals only.  Disclaimer:   This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.  The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program  The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits    Speaker disclosures:   Dr. Seema Aceves: Research funding: NIH, NIAID, NIDDK . Honoraria and/or consultation fees: AstraZeneca, Medscape, UpToDate, Regeneron, Sanofi, Ferring . Other support: Royalties, Co-inventor, oral viscous budesonide (UCSD-patented, Takeda-licensed)  Ms. Hilary Ugras: Consultant/Speaker/Advisory Board: Regeneron, Sanofi, Takeda  © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.  MAT-GLB-2506205 - 1.0  - 01/2026  MAT-US-2512929 v1.0 - P Exp Date: 01/23/2028  Wed, 28 Jan 2026 13:47:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Hear Dr. Seema Aceves and Ms. Hilary Ugras discuss the importance of early diagnosis and intervention for patients with EoE, opportunities for early diagnosis, and unmasking the adaptive behaviors of patients with EoE.  ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  Learn more at ADVENTprogram.com.  This podcast is intended for healthcare professionals only.  Disclaimer:   This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.  The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program  The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits    Speaker disclosures:   Dr. Seema Aceves: Research funding: NIH, NIAID, NIDDK . Honoraria and/or consultation fees: AstraZeneca, Medscape, UpToDate, Regeneron, Sanofi, Ferring . Other support: Royalties, Co-inventor, oral viscous budesonide (UCSD-patented, Takeda-licensed)  Ms. Hilary Ugras: Consultant/Speaker/Advisory Board: Regeneron, Sanofi, Takeda  © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.  MAT-GLB-2506205 - 1.0  - 01/2026  MAT-US-2512929 v1.0 - P Exp Date: 01/23/2028  Hear Dr. Seema Aceves and Ms. Hilary Ugras discuss the importance of early diagnosis and intervention for patients with EoE, opportunities for early diagnosis, and unmasking the adaptive behaviors of patients with EoE. 

ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. 

Learn more at ADVENTprogram.com. 

This podcast is intended for healthcare professionals only. 

Disclaimer:  

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. 

  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program 

  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits 

 

Speaker disclosures:  

  • Dr. Seema Aceves: Research funding: NIH, NIAID, NIDDK . Honoraria and/or consultation fees: AstraZeneca, Medscape, UpToDate, Regeneron, Sanofi, Ferring . Other support: Royalties, Co-inventor, oral viscous budesonide (UCSD-patented, Takeda-licensed) 
  • Ms. Hilary Ugras: Consultant/Speaker/Advisory Board: Regeneron, Sanofi, Takeda 

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 

MAT-GLB-2506205 - 1.0  - 01/2026 

MAT-US-2512929 v1.0 - P Exp Date: 01/23/2028 

]]> 1096 Predictors of Recurrence in CRSwNP Hear Drs. Katie Buchheit and Martin Wagenmann discuss the rates of recurrence following endoscopic sinus surgery for patients with CRSwNP and different methods of predicting which patients will respond well to surgery and which patients would fare better with a different approach. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Katie Buchheit: K. Buchheit has served on scientific advisory boards and/or received honoraria from AstraZeneca, Regeneron, Sanofi-Genzyme, Eli Lilly and GlaxoSmithKline, receives royalties from UpToDate, and receives research funding from NIH/NIAID and Regeneron. Dr. Martin Wagenmann: Fees for lectures and / or participation in scientific advisory boards: Advanz Pharma, ALK-Abelló, Allergopharma, AstraZeneca, Celltrion, CSL Behring, GSK, HAL Allergie, med update, MSD, NeilMed, Regeneron, Sanofi, Stallergenes, Streamed Up; Grants (to institution): ALK-Abelló, AstraZeneca, EU, GSK, Novartis, Regeneron, Sanofi, Takeda © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2506006 - 1.0  - 1/2026 MAT-US-2600233 v1.0 - P Exp Date: 01/07/2028 Mon, 26 Jan 2026 13:09:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Hear Drs. Katie Buchheit and Martin Wagenmann discuss the rates of recurrence following endoscopic sinus surgery for patients with CRSwNP and different methods of predicting which patients will respond well to surgery and which patients would fare better with a different approach. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Katie Buchheit: K. Buchheit has served on scientific advisory boards and/or received honoraria from AstraZeneca, Regeneron, Sanofi-Genzyme, Eli Lilly and GlaxoSmithKline, receives royalties from UpToDate, and receives research funding from NIH/NIAID and Regeneron. Dr. Martin Wagenmann: Fees for lectures and / or participation in scientific advisory boards: Advanz Pharma, ALK-Abelló, Allergopharma, AstraZeneca, Celltrion, CSL Behring, GSK, HAL Allergie, med update, MSD, NeilMed, Regeneron, Sanofi, Stallergenes, Streamed Up; Grants (to institution): ALK-Abelló, AstraZeneca, EU, GSK, Novartis, Regeneron, Sanofi, Takeda © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2506006 - 1.0  - 1/2026 MAT-US-2600233 v1.0 - P Exp Date: 01/07/2028 Hear Drs. Katie Buchheit and Martin Wagenmann discuss the rates of recurrence following endoscopic sinus surgery for patients with CRSwNP and different methods of predicting which patients will respond well to surgery and which patients would fare better with a different approach.


ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.


This podcast is intended for healthcare professionals only.

Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

Speaker disclosures:  

  • Dr. Katie Buchheit: K. Buchheit has served on scientific advisory boards and/or received honoraria from AstraZeneca, Regeneron, Sanofi-Genzyme, Eli Lilly and GlaxoSmithKline, receives royalties from UpToDate, and receives research funding from NIH/NIAID and Regeneron.
  • Dr. Martin Wagenmann: Fees for lectures and / or participation in scientific advisory boards: Advanz Pharma, ALK-Abelló, Allergopharma, AstraZeneca, Celltrion, CSL Behring, GSK, HAL Allergie, med update, MSD, NeilMed, Regeneron, Sanofi, Stallergenes, Streamed Up; Grants (to institution): ALK-Abelló, AstraZeneca, EU, GSK, Novartis, Regeneron, Sanofi, Takeda

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.


MAT-GLB-2506006 - 1.0  - 1/2026

MAT-US-2600233 v1.0 - P Exp Date: 01/07/2028

]]> 1287 Best Practice for CSU - Perspectives from Allergy and Dermatology Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria. offering practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Nicole Chase, MD, has the following interests to disclose: ALK, Amgen, Apogee, ARS, AstraZeneca, Aquestive, Blueprint, Cogent, Eli Lilly, Genentech, Illuminate Health, Incyte, MJH Life Sciences, Novartis, Onviv, Regeneron, Sanofi, Regeneron, Vindico. Jason Hawkes, MD, MS has the following interests to disclose: Medical Board, National Psoriasis Foundation Scientific Advisory Committee, Apogee, Arcutis Biotherapeutics, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Boxer Capital LLC, Cogent Biosciences, Galderma, Institute for Systems Biology, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi, SUN Pharma, Takeda, UCB. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB- MAT-GLB-2506315 – 1.0 – 01/2026 MAT-US-2514202 v1.0 - P Expiration Date: 12/24/2027 Fri, 09 Jan 2026 08:25:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria. offering practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Nicole Chase, MD, has the following interests to disclose: ALK, Amgen, Apogee, ARS, AstraZeneca, Aquestive, Blueprint, Cogent, Eli Lilly, Genentech, Illuminate Health, Incyte, MJH Life Sciences, Novartis, Onviv, Regeneron, Sanofi, Regeneron, Vindico. Jason Hawkes, MD, MS has the following interests to disclose: Medical Board, National Psoriasis Foundation Scientific Advisory Committee, Apogee, Arcutis Biotherapeutics, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Boxer Capital LLC, Cogent Biosciences, Galderma, Institute for Systems Biology, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi, SUN Pharma, Takeda, UCB. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB- MAT-GLB-2506315 – 1.0 – 01/2026 MAT-US-2514202 v1.0 - P Expiration Date: 12/24/2027 Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria. offering practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


This podcast is intended for healthcare professionals only.


Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.

Speaker disclosures:

  • Nicole Chase, MD, has the following interests to disclose: ALK, Amgen, Apogee, ARS, AstraZeneca, Aquestive, Blueprint, Cogent, Eli Lilly, Genentech, Illuminate Health, Incyte, MJH Life Sciences, Novartis, Onviv, Regeneron, Sanofi, Regeneron, Vindico.
  • Jason Hawkes, MD, MS has the following interests to disclose: Medical Board, National Psoriasis Foundation Scientific Advisory Committee, Apogee, Arcutis Biotherapeutics, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Boxer Capital LLC, Cogent Biosciences, Galderma, Institute for Systems Biology, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi, SUN Pharma, Takeda, UCB.


© 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB- MAT-GLB-2506315 – 1.0 – 01/2026

MAT-US-2514202 v1.0 - P Expiration Date: 12/24/2027

]]> 1732 Eosinophilic Esophagitis: Steering Toward Success Hear Drs Evan Dellon and Joshua Wechsler discuss EoE assessment utilizing the latest guidance from both US and European guidelines. Join them as they discuss current approaches to assess treatment response, the need for maintenance therapy, and the importance of follow-up and looking beyond symptom improvement to define therapeutic success.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Evan Dellon: Research funding:  Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; Consultant:  Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; Educational grant:  Allakos, Aqilion, Holoclara, Invea  Dr. Joshua Wechsler: Medical advisory/speaker/consultant: Regeneron/Sanofi; Consultant: AstraZeneca, Ellodi, Celldex; Medical Advisory: BMS  © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503560 - 2.0 - 12/2025 Tue, 09 Dec 2025 15:12:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Hear Drs Evan Dellon and Joshua Wechsler discuss EoE assessment utilizing the latest guidance from both US and European guidelines. Join them as they discuss current approaches to assess treatment response, the need for maintenance therapy, and the importance of follow-up and looking beyond symptom improvement to define therapeutic success.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Evan Dellon: Research funding:  Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; Consultant:  Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; Educational grant:  Allakos, Aqilion, Holoclara, Invea  Dr. Joshua Wechsler: Medical advisory/speaker/consultant: Regeneron/Sanofi; Consultant: AstraZeneca, Ellodi, Celldex; Medical Advisory: BMS  © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503560 - 2.0 - 12/2025 Hear Drs Evan Dellon and Joshua Wechsler discuss EoE assessment utilizing the latest guidance from both US and European guidelines. Join them as they discuss current approaches to assess treatment response, the need for maintenance therapy, and the importance of follow-up and looking beyond symptom improvement to define therapeutic success.  



ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  


This podcast is intended for healthcare professionals only.

Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

Speaker disclosures:  

  • Dr. Evan Dellon: Research funding:  Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; Consultant:  Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; Educational grant:  Allakos, Aqilion, Holoclara, Invea 
  • Dr. Joshua Wechsler: Medical advisory/speaker/consultant: Regeneron/Sanofi; Consultant: AstraZeneca, Ellodi, Celldex; Medical Advisory: BMS 

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.


MAT-GLB-2503560 - 2.0 - 12/2025

]]> 1019 Burden of Disease and Diagnosis Drs Donna Culton and Russell Hall explore the Burden of Disease and Diagnosis of BP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Dr. Culton - Consultant/advisory board or principal investigator: Argenx, Cabaletta, iCell, Incyte, Janssen, Lilly, Regeneron, Sanofi Genzyme, Sitala  Dr. Hall - Consultant and/or grant: Argenx, Sanofi/Regeneron, GycoEra, NUVIG, Immunovant, Innovaderm, Priovan Therapeutics    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. AllRights Reserved. MAT-GLB-2501573 – 1.0 – 06/2025 Wed, 27 Aug 2025 13:10:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE full ADVENT Program Drs Donna Culton and Russell Hall explore the Burden of Disease and Diagnosis of BP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Dr. Culton - Consultant/advisory board or principal investigator: Argenx, Cabaletta, iCell, Incyte, Janssen, Lilly, Regeneron, Sanofi Genzyme, Sitala  Dr. Hall - Consultant and/or grant: Argenx, Sanofi/Regeneron, GycoEra, NUVIG, Immunovant, Innovaderm, Priovan Therapeutics    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. AllRights Reserved. MAT-GLB-2501573 – 1.0 – 06/2025 Drs Donna Culton and Russell Hall explore the Burden of Disease and Diagnosis of BP.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

 

This podcast is intended for healthcare professionals only.

 

Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.

Speaker disclosures:

  • Dr. Culton - Consultant/advisory board or principal investigator: Argenx, Cabaletta, iCell, Incyte, Janssen, Lilly, Regeneron, Sanofi Genzyme, Sitala 
  • Dr. Hall - Consultant and/or grant: Argenx, Sanofi/Regeneron, GycoEra, NUVIG, Immunovant, Innovaderm, Priovan Therapeutics 

 

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. AllRights Reserved.

MAT-GLB-2501573 – 1.0 – 06/2025

]]> 1142 Exploring the Urgency to Treat Patients with Atopic Dermatitis Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027 Thu, 27 Feb 2025 17:18:22 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Exploring the Urgency to Treat Patients with Atopic Dermatitis full ADVENT Program Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027 Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.

 

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

 

This podcast is intended for healthcare professionals only.

 

Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.

 

Speaker disclosures:

  • Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. 

 

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2407353  – 1.0 – 02/2025

MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

]]> 887 Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Mario Castro, MD, MPH, reports grants and research support from NIH, ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance. He receives consulting fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead Pharmaceuticals, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, and GSK. He receives payment for speaker bureau activities from Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis, and Teva. He also receives stock options from Aer Therapeutics. Vibeke Backer, MD, has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401489 – 1.0 – 10/2024 MAT-US-2410093 v1.0 – P Expiration Date: 10/09/2026 Wed, 23 Oct 2024 09:18:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma full ADVENT Program Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Mario Castro, MD, MPH, reports grants and research support from NIH, ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance. He receives consulting fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead Pharmaceuticals, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, and GSK. He receives payment for speaker bureau activities from Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis, and Teva. He also receives stock options from Aer Therapeutics. Vibeke Backer, MD, has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401489 – 1.0 – 10/2024 MAT-US-2410093 v1.0 – P Expiration Date: 10/09/2026 Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

 

This podcast is intended for healthcare professionals only.

 

Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.


Speaker disclosures:

  • Mario Castro, MD, MPH, reports grants and research support from NIH, ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance. He receives consulting fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead Pharmaceuticals, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, and GSK. He receives payment for speaker bureau activities from Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis, and Teva. He also receives stock options from Aer Therapeutics.
  • Vibeke Backer, MD, has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2401489 – 1.0 – 10/2024

MAT-US-2410093 v1.0 – P Expiration Date: 10/09/2026

]]> 1145 Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Theresa Guilbert, MD, reports grants from GSK, grants from NIH, grants and consult fees from Sanofi/Regeneron/Amgen, grants and consult fees from AstraZeneca, consult fees from Genentech, consult fees from Polarean, grants and consult fees from OM Pharma, consult fees from AiCME, consult fees from Best Pharmaceuticals for Children Act (BPCA), consult fees from PlatformQ health, royalties from UpToDate.  Wanda Phipatanakul MD, MS, consults for Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401186 - 1.0  - 08/2024 MAT-US-2408147 v1.0 - P Exp Date: 08/14/2026 Mon, 26 Aug 2024 13:51:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond full ADVENT Program Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Theresa Guilbert, MD, reports grants from GSK, grants from NIH, grants and consult fees from Sanofi/Regeneron/Amgen, grants and consult fees from AstraZeneca, consult fees from Genentech, consult fees from Polarean, grants and consult fees from OM Pharma, consult fees from AiCME, consult fees from Best Pharmaceuticals for Children Act (BPCA), consult fees from PlatformQ health, royalties from UpToDate.  Wanda Phipatanakul MD, MS, consults for Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401186 - 1.0  - 08/2024 MAT-US-2408147 v1.0 - P Exp Date: 08/14/2026 Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Theresa Guilbert, MD, reports grants from GSK, grants from NIH, grants and consult fees from Sanofi/Regeneron/Amgen, grants and consult fees from AstraZeneca, consult fees from Genentech, consult fees from Polarean, grants and consult fees from OM Pharma, consult fees from AiCME, consult fees from Best Pharmaceuticals for Children Act (BPCA), consult fees from PlatformQ health, royalties from UpToDate. 
  • Wanda Phipatanakul MD, MS, consults for Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2401186 - 1.0  - 08/2024

MAT-US-2408147 v1.0 - P Exp Date: 08/14/2026

]]> 1338 Exploring PN as a Distinct and Unique Disease Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L’Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400085- 1.0 - 08/2024 MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026 Thu, 15 Aug 2024 07:32:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Exploring PN as a Distinct and Unique Disease full ADVENT Program Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L’Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400085- 1.0 - 08/2024 MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026 Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi.
  • Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L’Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2400085- 1.0 - 08/2024

MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026

]]> 1837 Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.  © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401395 - 1.0 - 07/2024 MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026 Thu, 08 Aug 2024 13:15:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD full ADVENT Program Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.  © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401395 - 1.0 - 07/2024 MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026 Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx
  • Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. 


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2401395 - 1.0 - 07/2024

MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026

]]> 1384 First-hand Experience: Practical Insights on the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2402602- 1.0 - 05/2024 MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026 Thu, 06 Jun 2024 17:19:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE First-hand Experience: Practical Insights on the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet full ADVENT Program Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2402602- 1.0 - 05/2024 MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026 Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer.
  • Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2402602- 1.0 - 05/2024

MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026

]]> 651 Getting to Grips with Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients? Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024  MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026 Thu, 06 Jun 2024 08:01:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Getting to Grips with Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients? full ADVENT Program Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024  MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026 Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer.
  • Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2400314 - 1.0 - 06/2024 

MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026

]]> 1070 More Than Just Difficulty Swallowing: Disease Burden and Diagnosis of EoE Dr. Joshua Wechsler and Prof. Arjan Bredenoord discuss the burden of disease in patients with EoE, the impact on quality of life, and how to overcome challenges in identifying EoE. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Arjan Bredenoord, MD, PhD (Adult Gastroenterologist): Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands Joshua Wechsler, MD, MSci (Pediatric Gastroenterologist): Attending Physician, Division of Gastroenterology, Hepatology & Nutrition; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar; Medical Director, Eosinophilic Gastrointestinal Disorders Program; Assistant Professor in Pediatrics & Medicine, Northwestern University – The Feinberg School of Medicine © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304791 - 1.0 - 05/2024 MAT-US-2404998 v1.0  - P Expiration Date: 05/15/2026 Tue, 21 May 2024 12:43:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE More Than Just Difficulty Swallowing: Disease Burden and Diagnosis of EoE full ADVENT Program Dr. Joshua Wechsler and Prof. Arjan Bredenoord discuss the burden of disease in patients with EoE, the impact on quality of life, and how to overcome challenges in identifying EoE. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Arjan Bredenoord, MD, PhD (Adult Gastroenterologist): Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands Joshua Wechsler, MD, MSci (Pediatric Gastroenterologist): Attending Physician, Division of Gastroenterology, Hepatology & Nutrition; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar; Medical Director, Eosinophilic Gastrointestinal Disorders Program; Assistant Professor in Pediatrics & Medicine, Northwestern University – The Feinberg School of Medicine © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304791 - 1.0 - 05/2024 MAT-US-2404998 v1.0  - P Expiration Date: 05/15/2026 Dr. Joshua Wechsler and Prof. Arjan Bredenoord discuss the burden of disease in patients with EoE, the impact on quality of life, and how to overcome challenges in identifying EoE.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Arjan Bredenoord, MD, PhD (Adult Gastroenterologist): Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands
  • Joshua Wechsler, MD, MSci (Pediatric Gastroenterologist): Attending Physician, Division of Gastroenterology, Hepatology & Nutrition; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar; Medical Director, Eosinophilic Gastrointestinal Disorders Program; Assistant Professor in Pediatrics & Medicine, Northwestern University – The Feinberg School of Medicine


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2304791 - 1.0 - 05/2024

MAT-US-2404998 v1.0  - P Expiration Date: 05/15/2026

]]> 755 Remission in CRSwNP Professor Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Professor Peter Hellings has received clinical trial funding and/or advisory board fees from Sanofi, Novartis, GlaxoSmithKline, Stallergenes, ALK, Viatris/Mylan. Doctor Stella Lee has received clinical trial funding and/or advisory board fees from AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, OptiNose, Sanofi and Regeneron. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400409 v1.0 03/2024 MAT-US-2402818 v1.0 - P Expiration Date: 03/12/2026 Fri, 29 Mar 2024 04:00:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Remission in CRSwNP full ADVENT Program Professor Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Professor Peter Hellings has received clinical trial funding and/or advisory board fees from Sanofi, Novartis, GlaxoSmithKline, Stallergenes, ALK, Viatris/Mylan. Doctor Stella Lee has received clinical trial funding and/or advisory board fees from AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, OptiNose, Sanofi and Regeneron. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400409 v1.0 03/2024 MAT-US-2402818 v1.0 - P Expiration Date: 03/12/2026 Professor Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.

 

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.


Speaker disclosures:

  • Professor Peter Hellings has received clinical trial funding and/or advisory board fees from Sanofi, Novartis, GlaxoSmithKline, Stallergenes, ALK, Viatris/Mylan.
  • Doctor Stella Lee has received clinical trial funding and/or advisory board fees from AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, OptiNose, Sanofi and Regeneron.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2400409 v1.0 03/2024

MAT-US-2402818 v1.0 - P Expiration Date: 03/12/2026

]]> 1146 The Road Ahead: Achieving Remission for Patients with Asthma Join renowned pulmonologists Klaus Rabe, MD, PhD, FERS, and Ian Pavord, DM, FRCP, FERS, as they discuss on-treatment clinical remission as a goal in asthma management beyond disease control, and highlight the role of type 2 inflammatory biomarkers in optimizing patient outcomes. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci has received honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.  Klaus Rabe, MD, PhD has served on FDA and EMA panels for registration of drug for COPD. He has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Sanofi & Regeneron, Berlin Chemie, Novartis, GlaxoSmithKline, Insmed, CSL Behring making asthma and COPD drugs, and participated in clinical trials. He has never worked with the tobacco industry (and never will). He has no shares or proprietary interests of any kind. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303834 V1 02/2024 MAT-US-2402193 v1.0 - P Expiration Date: 02/26/2026 Thu, 07 Mar 2024 10:58:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE The Road Ahead: Achieving Remission for Patients with Asthma full ADVENT Program Join renowned pulmonologists Klaus Rabe, MD, PhD, FERS, and Ian Pavord, DM, FRCP, FERS, as they discuss on-treatment clinical remission as a goal in asthma management beyond disease control, and highlight the role of type 2 inflammatory biomarkers in optimizing patient outcomes. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci has received honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.  Klaus Rabe, MD, PhD has served on FDA and EMA panels for registration of drug for COPD. He has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Sanofi & Regeneron, Berlin Chemie, Novartis, GlaxoSmithKline, Insmed, CSL Behring making asthma and COPD drugs, and participated in clinical trials. He has never worked with the tobacco industry (and never will). He has no shares or proprietary interests of any kind. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303834 V1 02/2024 MAT-US-2402193 v1.0 - P Expiration Date: 02/26/2026 Join renowned pulmonologists Klaus Rabe, MD, PhD, FERS, and Ian Pavord, DM, FRCP, FERS, as they discuss on-treatment clinical remission as a goal in asthma management beyond disease control, and highlight the role of type 2 inflammatory biomarkers in optimizing patient outcomes.


ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer:

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.


Speaker disclosures:

  • Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci has received honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva. 
  • Klaus Rabe, MD, PhD has served on FDA and EMA panels for registration of drug for COPD. He has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Sanofi & Regeneron, Berlin Chemie, Novartis, GlaxoSmithKline, Insmed, CSL Behring making asthma and COPD drugs, and participated in clinical trials. He has never worked with the tobacco industry (and never will). He has no shares or proprietary interests of any kind.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2303834 V1 02/2024

MAT-US-2402193 v1.0 - P Expiration Date: 02/26/2026

]]> 950 Exploring Loss of Smell in CRSwNP: Clinical Relevance and Patient Impact Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.  Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400013 v1.0 01/2024 MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026 Fri, 19 Jan 2024 14:24:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Exploring Loss of Smell in CRSwNP: Clinical Relevance and Patient Impact full ADVENT Program Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.  Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400013 v1.0 01/2024 MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026 Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic. 
  • Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris.


© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2400013 v1.0 01/2024

MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026

]]> 1024 What Is the Future Outlook for Remission in Pediatric Severe Asthma? Listen to Len Bacharier, MD and Sharon Dell, MD, FRCPC, as they highlight the natural course of pediatric asthma progression over time, discuss differences between spontaneous remission and on-treatment clinical remission, and provide a commentary on what we have learned from the recent developments around remission in adults and how it could relate more specifically to pediatric populations.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Len Bacharier, MD has served as an advisor, consultant, speaker, and/or investigator for AstraZeneca, Avillion, DBV Technologies, Genentech/Novartis, GlaxoSmithKline, Kinaset, OM Pharma, Recludix, Regeneron Pharmaceuticals, Inc., Sanofi, Vertex; has provided grant and/or research support for NIH (NHLBI, NIAID), Regeneron Pharmaceuticals, Inc., Sanofi; and has provided other support for DBV Technologies Sharon Dell, MD has served as an advisor, consultant, and/or speaker for  AstraZeneca, Novartis, Regeneron Pharmaceuticals, Sanofi; and has provided grant and/or research support for Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, Vertex Pharmaceuticals © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2305935 v1.0 12/2023 MAT-US-2305475 v1.0 - P Expiration Date: 12/22/2025 Fri, 05 Jan 2024 10:46:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE What Is the Future Outlook for Remission in Pediatric Severe Asthma? full ADVENT Program Listen to Len Bacharier, MD and Sharon Dell, MD, FRCPC, as they highlight the natural course of pediatric asthma progression over time, discuss differences between spontaneous remission and on-treatment clinical remission, and provide a commentary on what we have learned from the recent developments around remission in adults and how it could relate more specifically to pediatric populations.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Len Bacharier, MD has served as an advisor, consultant, speaker, and/or investigator for AstraZeneca, Avillion, DBV Technologies, Genentech/Novartis, GlaxoSmithKline, Kinaset, OM Pharma, Recludix, Regeneron Pharmaceuticals, Inc., Sanofi, Vertex; has provided grant and/or research support for NIH (NHLBI, NIAID), Regeneron Pharmaceuticals, Inc., Sanofi; and has provided other support for DBV Technologies Sharon Dell, MD has served as an advisor, consultant, and/or speaker for  AstraZeneca, Novartis, Regeneron Pharmaceuticals, Sanofi; and has provided grant and/or research support for Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, Vertex Pharmaceuticals © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2305935 v1.0 12/2023 MAT-US-2305475 v1.0 - P Expiration Date: 12/22/2025 Listen to Len Bacharier, MD and Sharon Dell, MD, FRCPC, as they highlight the natural course of pediatric asthma progression over time, discuss differences between spontaneous remission and on-treatment clinical remission, and provide a commentary on what we have learned from the recent developments around remission in adults and how it could relate more specifically to pediatric populations.

 

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Len Bacharier, MD has served as an advisor, consultant, speaker, and/or investigator for AstraZeneca, Avillion, DBV Technologies, Genentech/Novartis, GlaxoSmithKline, Kinaset, OM Pharma, Recludix, Regeneron Pharmaceuticals, Inc., Sanofi, Vertex; has provided grant and/or research support for NIH (NHLBI, NIAID), Regeneron Pharmaceuticals, Inc., Sanofi; and has provided other support for DBV Technologies
  • Sharon Dell, MD has served as an advisor, consultant, and/or speaker for  AstraZeneca, Novartis, Regeneron Pharmaceuticals, Sanofi; and has provided grant and/or research support for Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, Vertex Pharmaceuticals


© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2305935 v1.0 12/2023

MAT-US-2305475 v1.0 - P Expiration Date: 12/22/2025

]]> 1448 Clinical Perspective on Pediatric Patients With Atopic Dermatitis Join Drs. Lisa Swanson and Weily Soong as they provide clinical perspectives on the care of pediatric patients with atopic dermatitis (AD) and discuss unmet needs, addressing coexisting diseases, and the role of the interdisciplinary team and caregivers in the management of AD in pediatric patients. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303452 V1 11/2023 MAT-US-2305632 v1.0 - P Expiration Date: 11/1/2025 Mon, 13 Nov 2023 12:30:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Clinical Perspective on Pediatric Patients With Atopic Dermatitis full ADVENT Program Join Drs. Lisa Swanson and Weily Soong as they provide clinical perspectives on the care of pediatric patients with atopic dermatitis (AD) and discuss unmet needs, addressing coexisting diseases, and the role of the interdisciplinary team and caregivers in the management of AD in pediatric patients. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303452 V1 11/2023 MAT-US-2305632 v1.0 - P Expiration Date: 11/1/2025 Join Drs. Lisa Swanson and Weily Soong as they provide clinical perspectives on the care of pediatric patients with atopic dermatitis (AD) and discuss unmet needs, addressing coexisting diseases, and the role of the interdisciplinary team and caregivers in the management of AD in pediatric patients.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB
  • Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica


© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2303452 V1 11/2023

MAT-US-2305632 v1.0 - P Expiration Date: 11/1/2025

]]> 988 Getting to the Diagnosis of Atopic Dermatitis in Pediatric Patients Learn more about the journey to diagnosis for pediatric patients with atopic dermatitis. Join Drs. Lisa Swanson and Weily Soong as they explore diagnosis and assessment of pediatric atopic dermatitis (AD), determining AD disease severity, and the impact of delayed diagnosis on a patient’s physical and psychological health. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303453 V1 10/2023 MAT-US-2309379 v1.0 - P Expiration Date: 10/6/2025 Mon, 09 Oct 2023 15:15:17 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Getting to the Diagnosis of Atopic Dermatitis in Pediatric Patients full ADVENT Program Learn more about the journey to diagnosis for pediatric patients with atopic dermatitis. Join Drs. Lisa Swanson and Weily Soong as they explore diagnosis and assessment of pediatric atopic dermatitis (AD), determining AD disease severity, and the impact of delayed diagnosis on a patient’s physical and psychological health. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303453 V1 10/2023 MAT-US-2309379 v1.0 - P Expiration Date: 10/6/2025 Learn more about the journey to diagnosis for pediatric patients with atopic dermatitis. Join Drs. Lisa Swanson and Weily Soong as they explore diagnosis and assessment of pediatric atopic dermatitis (AD), determining AD disease severity, and the impact of delayed diagnosis on a patient’s physical and psychological health.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

Speaker disclosures:

  • Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB
  • Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica


© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2303453 V1 10/2023

MAT-US-2309379 v1.0 - P Expiration Date: 10/6/2025

]]> 1033 Defining Atopic Dermatitis in Pediatric Patients Learn more about the journey for pediatric patients with atopic dermatitis. Join Drs. Lisa Swanson and Weily Soong as they discuss the hallmarks of atopic dermatitis (AD) and explore the clinical presentation, disease trajectories, and burden on patients and caregivers associated with pediatric AD.  ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303454 V1 10/2023  MAT-US-2305628 v1.0 - P Expiration Date: 8/2/2025 Mon, 09 Oct 2023 15:14:53 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Defining Atopic Dermatitis in Pediatric Patients full ADVENT Program Learn more about the journey for pediatric patients with atopic dermatitis. Join Drs. Lisa Swanson and Weily Soong as they discuss the hallmarks of atopic dermatitis (AD) and explore the clinical presentation, disease trajectories, and burden on patients and caregivers associated with pediatric AD.  ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2303454 V1 10/2023  MAT-US-2305628 v1.0 - P Expiration Date: 8/2/2025 Learn more about the journey for pediatric patients with atopic dermatitis. Join Drs. Lisa Swanson and Weily Soong as they discuss the hallmarks of atopic dermatitis (AD) and explore the clinical presentation, disease trajectories, and burden on patients and caregivers associated with pediatric AD. 

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Weily Soong, MD has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Allakos, Amgen, AstraZeneca, Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi, and UCB
  • Lisa Swanson, MD has served as a speaker for Abbvie, Almirall, Eli Lilly, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica; and as an advisory board consultant for Arcutis, Dermavant, Eli Lilly, Janssen, Leo, Novan, Ortho Dermatologics, Pfizer, Sanofi, Regeneron, and Verrica


© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2303454 V1 10/2023 

MAT-US-2305628 v1.0 - P Expiration Date: 8/2/2025

]]> 1138 Exploring Common Drivers of Type 2 Inflammatory Diseases Discover shared and unique features of type 2 inflammatory diseases and how multi-disciplinary care can benefit patients. Join Profs. Klaus Rabe and Stephan Weidinger as they explore how chronic underlying type 2 inflammation manifests in different organs to drive pathology in atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis; and discuss how these commonalities translate into shared decision-making and multidisciplinary care in clinical practice. ADVENT is a medical education non-promotional for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Klaus Rabe, MD, PhD: Grants and research support: German Federal Ministry for Research and Technology (BMFT); Honoraria or consultation fees: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi, Regeneron, Verona Pharma; Other support/potential conflict of interest: Director of the Airway Research Center North (ARCN) within the Deutsche Zentrum für Lungenforschung (DZL) Stephan Weidinger, MD, PhD: Speaker, advisory board member, and or investigator for: AbbVie, Almirall, Galderma, Kymab, Leo Pharma, Lilly, Pfizer, Regeneron, Sanofi, Boehringer Ingelheim © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302410 v2.0 07/2023 MAT-US-2304930 v1.0-P Exp. Date 07/07/2025 Mon, 31 Jul 2023 10:00:00 -0000 AU AT BE CA CO CR DO EC EG FR DE GT HK IT LB MO NL PA PE PL PT ES SD TW US CN BH KW OM QA AE Exploring Common Drivers of Type 2 Inflammatory Diseases full ADVENT Program Discover shared and unique features of type 2 inflammatory diseases and how multi-disciplinary care can benefit patients. Join Profs. Klaus Rabe and Stephan Weidinger as they explore how chronic underlying type 2 inflammation manifests in different organs to drive pathology in atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis; and discuss how these commonalities translate into shared decision-making and multidisciplinary care in clinical practice. ADVENT is a medical education non-promotional for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Klaus Rabe, MD, PhD: Grants and research support: German Federal Ministry for Research and Technology (BMFT); Honoraria or consultation fees: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi, Regeneron, Verona Pharma; Other support/potential conflict of interest: Director of the Airway Research Center North (ARCN) within the Deutsche Zentrum für Lungenforschung (DZL) Stephan Weidinger, MD, PhD: Speaker, advisory board member, and or investigator for: AbbVie, Almirall, Galderma, Kymab, Leo Pharma, Lilly, Pfizer, Regeneron, Sanofi, Boehringer Ingelheim © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302410 v2.0 07/2023 MAT-US-2304930 v1.0-P Exp. Date 07/07/2025 Discover shared and unique features of type 2 inflammatory diseases and how multi-disciplinary care can benefit patients. Join Profs. Klaus Rabe and Stephan Weidinger as they explore how chronic underlying type 2 inflammation manifests in different organs to drive pathology in atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis; and discuss how these commonalities translate into shared decision-making and multidisciplinary care in clinical practice.

ADVENT is a medical education non-promotional for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.


Disclaimer: 

  • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


Speaker disclosures:

  • Klaus Rabe, MD, PhD: Grants and research support: German Federal Ministry for Research and Technology (BMFT); Honoraria or consultation fees: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi, Regeneron, Verona Pharma; Other support/potential conflict of interest: Director of the Airway Research Center North (ARCN) within the Deutsche Zentrum für Lungenforschung (DZL)
  • Stephan Weidinger, MD, PhD: Speaker, advisory board member, and or investigator for: AbbVie, Almirall, Galderma, Kymab, Leo Pharma, Lilly, Pfizer, Regeneron, Sanofi, Boehringer Ingelheim


© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

MAT-GLB-2302410 v2.0 07/2023

MAT-US-2304930 v1.0-P Exp. Date 07/07/2025

]]> 978